TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22240593
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR (80 mg/day)
Study: 22240593
Drug: Carvedilol IR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol IR (5-20 mg/day)
Study: 17544156
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg IV dexamethasone (n=50)
Study: 8477913
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg quinine HCl
Study: 8477913
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg quinine HCl
Study: 8477913
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg quinine HCl
Study: 7031187
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg)
Study: 23733756
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) 3,000 mg per day
Study: 12828985
Drug: 0.05M lactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05M lactic acid gel (6% w/v hydroxyethyl cellulose, pH 4.5) with fluoride for 7 days
Study: 12828985
Drug: 0.05M lactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05M lactic acid gel (6% w/v hydroxyethyl cellulose, pH 4.5) without fluoride for 7 days
Study: 8880847
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg plus 50, 100 or 200 mg of caffeine
Study: 1719654
Drug: Iloprost (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (maximum tolerated dose up to 2 ng/kg/min, administered as a six-hourly intravenous infusion for two to four weeks)
Study: 12839217
Drug: Fegan's technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fegan's technique using a combination of Aethoxysclerol and Fibrovein
Study: 8669574
Drug: Traditional training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional training group (performed ten nasendoscopies on anaesthetised oral surgery inpatients)
Study: 6364334
Drug: Metronidazole 2000
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 2000 mg in a single dose
Study: 6364334
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg three times daily for 5 days
Study: 31854293
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (42% of patients)
Study: 31854293
Drug: Guideline-recommended therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended therapy (58% of patients)
Study: 31854293
Drug: High mean
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High mean systolic blood pressure after blood pressure-lowering therapy
Study: 24807329
Drug: Topical aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aqueous 4% lidocaine
Study: 21988083
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation intervention (daily nurse-led, individual-based activities)
Study: 20329606
Drug: Qingshen Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingshen Granule (QSG), 1 bag thrice a day by oral intake for 1 month
Study: 20329606
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional Western medical therapy + retention enema of Jiedu Xiezhuo No. II)
Study: 16275213
Drug: Therapy responders
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy responders
Study: 12095880
Drug: Tretinoin cream
Normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin cream 0.05%
Study: 10463682
Drug: Thimerosal-preserved vaccine
Normalized name: Thimerosal
DrugBank: Thimerosal (DB11590)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thimerosal-preserved vaccine
Study: 10463682
Drug: Autoclaved vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autoclaved vaccine
Study: 1262709
Drug: Lyophilized vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized vaccine
Study: 7607607
Drug: Fructose infusion
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose infusion (15 min iv infusion at 0.185 mmol/kg BW/min)
Study: 1977761
Drug: Clonidine (0.150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.150 mg, orally) followed by GHRH (1 micrograms/kg, iv) at 180 min
Study: 1977761
Drug: Clonidine (0.150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.150 mg, orally) at 0 min followed by GHRH at 60 min and again at 180 min
Study: 17335818
Drug: Metformin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,500 mg/d)
Study: 25818049
Drug: 80mg of
Normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg of propranolol hydrochloride (β1 and β2 adrenergic receptor antagonist)
Study: 25818049
Drug: Microcrystalline cellulose
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose (placebo pill)
Study: 15612964
Drug: Zafirlukast, 20
Normalized name: Zafirlukast, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast, 20 mg bd
Study: 15612964
Drug: Theophylline, 200
Normalized name: Theophylline, 200 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline, 200 mg bd
Study: 12572722
Drug: Ciclopiroxolamine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopiroxolamine cream 11% (group A)
Study: 12572722
Drug: Ciclopiroxolamine solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopiroxolamine solution 1% (group B)
Study: 9435425
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (0.125 U/kg per week for 1 month and 0.25 U/kg per week for 5 months)
Study: 2568817
Drug: Iopromide 370
Normalized name: IOPROMIDE 370mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide 370 (2 ml/kg body weight)
Study: 2568817
Drug: Iopamidol 370
Normalized name: iopamidol 370 mg iodine/mL (76 %) INTRAVEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol 370 (2 ml/kg body weight)
Study: 2568817
Drug: Sodium meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium meglumine diatrizoate 370 (2 ml/kg body weight)
Study: 31604062
Drug: 44 g
Normalized name: PETROLATUM 44 g in 100 g TOPICAL OINTMENT [Dermaphor]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 g (250 kcal) pistachios consumed mid‐morning
Study: 24106072
Drug: Sildenafil (optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (optimized dose)
Study: 16784743
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine formula
Study: 15068413
Drug: 1 week
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 week of therapy (lansoprazole 30 mg b.i.d., amoxycillin 1 g b.i.d., tinidazole 500 mg b.i.d.)
Study: 15068413
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of therapy (lansoprazole 30 mg b.i.d., amoxycillin 1 g b.i.d., tinidazole 500 mg b.i.d.)
Study: 15068413
Drug: 3 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks of therapy (lansoprazole 30 mg b.i.d., amoxycillin 1 g b.i.d., tinidazole 500 mg b.i.d.)
Study: 1673505
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol intake (26 g alcohol daily)
Study: 7181084
Drug: Cimetidine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (oral and intramuscular)
Study: 7181084
Drug: Intramuscular Cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular Cimetidine
Study: 25184862
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan plus stem-cell transplantation
Study: 22571202
Drug: Lenalidomide maintenance
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide maintenance therapy
Study: 25184862
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan
Study: 22529964
Drug: HIV vaccine
Normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV vaccine (placebo-controlled trial)
Study: 2598983
Drug: Intravenous nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nifedipine (0.75 mg bolus and 1.2 mg.h‐1 infusion for 2 h)
Study: 2598983
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (20 mg sustained-release)
Study: 2598983
Drug: Vehicle alone
Normalized name: SUSPENDING VEHICLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle alone (control for intravenous study)
Study: 2598983
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control for oral study)
Study: 806518
Drug: Enteric-coated lactose
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated lactose tablets (Control)
Study: 31010413
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg once-daily (QD)
Study: 31010413
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by Duloxetine 60 mg QD (PLA_DLX)
Study: 31010413
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg QD (DLX_DLX)
Study: 21163595
Drug: Synthetic genistein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic genistein (30 mg daily)
Study: 12296616
Drug: Antidepressants, especially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants, especially selective serotonin uptake inhibitors
Study: 12296616
Drug: Early identification
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early identification and treatment
Study: 9833742
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (zidovudine + 400 mg didanosine + 400 mg nevirapine)
Study: 9833742
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (zidovudine + 2.25 mg zalcitabine)
Study: 9833742
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (zidovudine alternating monthly with 400 mg didanosine)
Study: 9833742
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (zidovudine + 400 mg didanosine)
Study: 7861603
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous administration of 20 micrograms.h‐1 of buprenorphine (Bu) with additional 20 micrograms of Bu using Baxter infusor BB+PCA
Study: 7861603
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of 0.4 mg of Bu and 46 ml of 0.25% bupivacaine daily (16.7 micrograms.h‐1 of Bu) using Baxter infusor 2 ml.h‐1 type
Study: 11791962
Drug: Amodiaquine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (30 and 35 mg/kg body weight)
Study: 23942868
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg CZP every 2 weeks (Q2W)
Study: 23942868
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg CZP every 4 weeks (Q4W)
Study: 21526671
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered for 30 seconds (Group A)
Study: 21526671
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered for 60 seconds (Group B)
Study: 21526671
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered for 120 seconds (Group C)
Study: 18034998
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg renzapride
Study: 18034998
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg renzapride
Study: 14872557
Drug: Ritalin LA
Normalized name: Ritalin LA
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritalin LA (bimodal release formulation)
Study: 14872557
Drug: Ritalin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritalin IR (immediate-release formulation)
Study: 14872557
Drug: Ritalin LA
Normalized name: Ritalin LA
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritalin LA (slow-, medium-, and fast-release formulations)
Study: 8593718
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg orally + ketoconazole shampoo 2% daily for 4 weeks
Study: 8593718
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg orally for 4 weeks
Study: 8593718
Drug: Econazole nitrate
Normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Econazole nitrate 1% solution applied twice daily for 4 weeks
Study: 8593718
Drug: Miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole nitrate 2% cream applied twice daily for 4 weeks
Study: 2678932
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) with haloperidol (30 mg/day)
Study: 1502960
Drug: Haloperidol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (30 mg/day)
Study: 1090987
Drug: Five drug
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five drug formulations
Study: 30753262
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (5 g glutamine and 10 g maltodextrin) 3 times daily from 7 days before RT to 14 days after RT
Study: 30753262
Drug: Placebo (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (15 g maltodextrin) 3 times daily from 7 days before RT to 14 days after RT
Study: 21919691
Drug: Ruxolitinib (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (15 or 20 mg twice daily)
Study: 25907176
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg canagliflozin once-daily (q.d.)
Study: 25907176
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg canagliflozin once-daily (q.d.)
Study: 25907176
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg canagliflozin twice-daily (b.i.d.)
Study: 25907176
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg canagliflozin twice-daily (b.i.d.)
Study: 25802729
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg canagliflozin
Study: 25500487
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg canagliflozin
Study: 19062107
Drug: Active counseling
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active counseling and more liberal oral fluid intake
Study: 16827026
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide exposure (33% for 30 minutes daily for five consecutive days) in Group I
Study: 16827026
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group II) received no treatment
Study: 14688827
Drug: Hepatitis G
Normalized name: Hepatitis G antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis G virus positivity in patients with Hodgkin's disease
Study: 8683153
Drug: mAb OKT3
Normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: mAb OKT3 infusion
Study: 1514334
Drug: 0.5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hyperbaric bupivacaine combined with 0.05 mg.kg‐1 meperidine
Study: 1514334
Drug: 0.5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hyperbaric bupivacaine combined with 0.1 mg.kg‐1 meperidine
Study: 1514334
Drug: 0.5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hyperbaric bupivacaine combined with 0.2 mg.kg‐1 meperidine
Study: 1514334
Drug: 0.5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hyperbaric bupivacaine combined with 0.3 mg.kg‐1 meperidine
Study: 1514334
Drug: 0.5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hyperbaric bupivacaine combined with 0.4 mg.kg‐1 meperidine
Study: 1514334
Drug: 0.5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hyperbaric bupivacaine combined with 0.5 mg.kg‐1 meperidine
Study: 27128199
Drug: Lopinavir/ritonavir syrups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir syrups
Study: 27128199
Drug: Lopinavir/ritonavir tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir tablets
Study: 23244011
Drug: Supportive psychodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive psychodynamic psychotherapy (SPP) in addition to treatment as usual (TaU)
Study: 21146658
Drug: Discharge antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discharge antiplatelet therapy (AT)
Study: 21146658
Drug: No discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: No discharge antiplatelet therapy (AT)
Study: 21146658
Drug: Discharge monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discharge monotherapy
Study: 12389066
Drug: Levosimendan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (2 mg i.v.)
Study: 12389066
Drug: Levosimendan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (2 mg i.v.) with carvedilol (25 mg orally, twice daily for 7-9 days)
Study: 26878875
Drug: SIT (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT (specific immunotherapy)
Study: 26878875
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no specific immunotherapy)
Study: 20628237
Drug: letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: letrozole (2.5 mg/day)
Study: 20628237
Drug: oxandrolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxandrolone (2.5 mg/day)
Study: 18381709
Drug: Pediatric antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric antidepressant treatment
Study: 16374149
Drug: 12 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mL/kg predicted body weight tidal volume group
Study: 16374149
Drug: 6 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL/kg predicted body weight tidal volume group
Study: 10894864
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m² on days 1, 8, and 15 and cisplatin 100 mg/m² on day 2, every 4 weeks (induction chemotherapy)
Study: 9373482
Drug: Hyaluronidase group
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase group (150 IU/ml hyaluronidase in anaesthetic solution)
Study: 1606337
Drug: Piggyback (PB)
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piggyback (PB) administration of lipids
Study: 3661391
Drug: Sex hormone
Normalized name: Sex hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormone levels (total and free testosterone, total and free estradiol, androstenedione, estrone) measured in cases and controls.
Study: 29443399
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous soybean oil (LOW)
Study: 29443399
Drug: Standard-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose intravenous soybean oil (CON)
Study: 19039919
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral hygiene treatment including plaque and calculus removal, root planing, motivation and instruction
Study: 19039919
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral hygiene treatment
Study: 15866609
Drug: Microdose GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microdose GnRH agonist protocol
Study: 15866609
Drug: Ganirelix acetate
Normalized name: Ganirelix Acetate
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganirelix acetate (GnRH antagonist protocol)
Study: 12766692
Drug: EX/RP with
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX/RP with medication
Study: 12766692
Drug: Serotonergic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonergic medications (fluvoxamine or clomipramine)
Study: 7579497
Drug: Mammography screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mammography screening (not specified dosage or duration)